Literature DB >> 27793445

Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.

Bo Qiu1, DeLing Wang2, Hong Yang3, WeiHao Xie1, Ying Liang4, Peiqiang Cai2, ZhaoLin Chen1, MengZhong Liu1, JianHua Fu3, ChuanMiao Xie2, Hui Liu5.   

Abstract

PURPOSE: To explore the value of combined modalities, including anatomical and functional magnetic resonance imaging (MRI), endoscopy and computed tomography (CT), for the assessment of tumor responses to definitive chemoradiotherapy (dCRT) in esophageal squamous cell carcinoma (ESCC).
METHODS: Sixty-seven patients with locally advanced ESCC were enrolled. Tumor response (TR) was assessed two months after the completion of dCRT. Evaluation criteria according to combined modalities, including MRI, endoscopy and CT, were established and compared with traditional criteria based on CT and endoscopy. Progression-free survival (PFS)⩾12months was used as the reference standard, and the accuracy of the two criteria in response assessment was analyzed.
RESULTS: Thirty-seven (55.2%) and 10 (14.9%) patients were considered to exhibit CR, as assessed by combined modalities and the traditional criteria, respectively. Using PFS⩾12months as a surrogate for CR, the sensitivity and specificity of the combined modalities were 82.4% and 88.9%, respectively, compared with 20.6% and 92.6% for the traditional criteria. TR assessed by combined modalities (CR vs. non-CR) was prognostic of PFS in univariate and multivariate analyses (Log-rank, P<0.0001; Cox regression, HR=0.114, 95% CI 0.048-0.272).
CONCLUSIONS: Tumor responses assessed by the combined modalities of MR, endoscopy and CT seemed highly predictive of prognosis after dCRT in ESCC patients. Copyright Â
© 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Computed tomography; Endoscopy; Esophageal squamous cell carcinoma; Magnetic resonance imaging; Response assessment

Mesh:

Year:  2016        PMID: 27793445     DOI: 10.1016/j.radonc.2016.09.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: additional evaluation by magnetic resonance imaging may help.

Authors:  Ta-Chen Huang; Chih-Hung Hsu
Journal:  Ann Transl Med       Date:  2017-12

2.  Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Wenbing Ji; Jian Wang; Rongzhen Zhou; Minke Wang; Weizhen Wang; Peipei Pang; Min Kong; Chao Zhou
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

3.  TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma.

Authors:  ShiLiang Liu; Bo Qiu; GuangYu Luo; Ying Liang; YuZhen Zheng; ZhaoLin Chen; KongJia Luo; Mian Xi; Qing Liu; YongHong Hu; Qun Li; JianHua Fu; MengZhong Liu; Hong Yang; Hui Liu
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

4.  A Prospective Phase II Study of Simultaneous Modulated Accelerated Radiotherapy Concurrently With CDDP/S1 for Esophageal Squamous Cell Carcinoma in the Elderly.

Authors:  SuPing Guo; FangJie Liu; Hui Liu; YingJia Wu; XuHui Zhang; WenFeng Ye; GuangYu Luo; QiWen Li; NaiBin Chen; Nan Hu; Bin Wang; Jun Zhang; MaoSheng Lin; HuiXia Feng; Bo Qiu
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

5.  Inter- and intra-observer reproducibility of ADC measurements in esophageal carcinoma primary tumors.

Authors:  Zhimin Ye; Jun Fang; Shujun Dai; Tieming Xie; Fangzheng Wang; Zhun Wang; Kai Li; Zhenfu Fu; Yuezhen Wang
Journal:  Oncotarget       Date:  2017-10-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.